300 George Street
New Haven, CT 06511
Associate Director, IR & Corporate Communications
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.
Our pipeline of drug candidates is comprised of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors. We believe our programs have a higher probability of success because they target specific markers or pathways in the disease or in the immune response to the disease. And due to our specific target approach, we are able to develop companion diagnostics designed to help us best define patient populations most likely to benefit from therapy. Our programs are specifically aimed at patient populations with high unmet medical need—including many underserved or completely un-served orphan indications. We currently sponsor clinical studies for patients who have triple negative breast cancer, metastatic melanoma, renal cell or ovarian carcinomas, head and neck squamous cell carcinoma and several other cancers.
Stock Symbol: CLDX
CT Employees: 26
US Employees: 195
World Employees: 196